<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> (FA) is an <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo>, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> susceptibility disorder characterized by diverse clinical features, such as <z:hpo ids='HP_0004322'>short stature</z:hpo>, skeletal or <z:mp ids='MP_0002096'>skin abnormalities</z:mp>, progressive bone marrow (BM) failure, and increased risk of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Clonal chromosomal abnormalities are frequently reported in FA patients transformed to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To study the incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and clonal chromosomal abnormalities in FA patients </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: Thirty-eight clinically diagnosed FA patients were studied at the time of diagnosis and the patients were followed-up for a maximum of 28 months at 3-month intervals </plain></SENT>
<SENT sid="4" pm="."><plain>The median duration of follow-up of these patients was 19.8 months </plain></SENT>
<SENT sid="5" pm="."><plain>Chromosomal breakage investigation using <z:chebi fb="0" ids="27504">mitomycin C</z:chebi> (<z:chebi fb="172" ids="27504">MMC</z:chebi>)- and <z:chebi fb="0" ids="23704">diepoxybutane</z:chebi> (<z:chebi fb="3" ids="23704">DEB</z:chebi>)-induced peripheral blood cultures were stimulated with phytohemagglutinin </plain></SENT>
<SENT sid="6" pm="."><plain>Cytogenetic study was done on the BM cells to detect clonal chromosomal aberrations </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Eleven (28.95%) out of 38 patients developed <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including 6 (54.54%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 4 (36.36%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and 1 (2.63%) <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The clonal chromosomal abnormalities were detected in 5 (45.45%) FA patients who developed <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and the type of chromosomal abnormality detected were <z:mp ids='MP_0004026'>monosomies</z:mp> 5, 7, <z:mp ids='MP_0004027'>trisomy</z:mp> 10, dup(1)(q12-q24), and inv(7)(p11pter) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The FA patients have a high risk of developing <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, and clonal chromosomal abnormalities play an important role in the prognosis of the disease </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, FA patients need to be followed-up at regular intervals for early diagnosis and optimal management of the disease </plain></SENT>
</text></document>